Javelin Biotech Publishes Multi-Tissue Chip and PBPK Study Showing Potential to Predict Human Drug Pharmacokinetics Without Animal Data
Javelin Biotech has announced the publication of a new scientific study that highlights the potential of advanced multi-microphysiological systems (multi-MPS) and computational modeling to improve the prediction of human drug pharmacokinetics before clinical testing. The paper, titled “Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics,” appears in the “Breakthrough” special issue of Lab on a Chip and describes a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic behavior of small-molecule drugs in a human-relevant laboratory setting.
The publication represents an important milestone for Javelin Biotech and for the broader field of New Approach Methodologies (NAMs), which seeks to reduce dependence on animal testing by using more predictive in vitro and computational tools. According to the company, the research demonstrates how data generated from interconnected organ-chip systems can be combined with physiologically based pharmacokinetic (PBPK) modeling to generate clinical exposure predictions that correlate strongly with observed human data.
In practical terms, the study aims to address one of the most persistent challenges in drug development: predicting how a drug will behave in the human body before it is tested in people. For small-molecule therapies—which still account for a large share of the pharmaceutical pipeline—understanding pharmacokinetics is essential. Developers need to know how a drug is absorbed, metabolized, distributed and eliminated in order to determine dosing, assess safety risks and estimate whether a candidate is likely to perform as intended in the clinic. Historically, much of this work has relied heavily on animal models, but those systems often fail to fully replicate human biology and can produce results that do not translate cleanly to human patients.
Javelin’s newly published study is positioned as evidence that a more human-relevant approach may be possible.
A liver-centered platform designed to model multiple dimensions of drug disposition
At the center of the research is Javelin Biotech’s multi-tissue chip platform, which integrates several organ-relevant systems into a single recirculating microfluidic environment. In the study, the company connected a liver microphysiological system with kidney and skeletal muscle components to create a platform capable of capturing multiple aspects of small-molecule pharmacokinetics simultaneously.
This design is significant because drug disposition in the body is rarely driven by a single organ. The liver is a central site of metabolism, the kidneys play a major role in excretion, and tissues such as muscle can contribute to the overall volume of distribution, influencing how widely a drug spreads through the body. Traditional in vitro systems often isolate one biological process at a time, making it difficult to model the integrated physiology that shapes real-world drug exposure in humans.
By contrast, Javelin’s multi-tissue chip is intended to recreate a more interconnected biological context. The company said the platform allows researchers to simultaneously assess hepatic metabolism, renal excretion, and distribution-related parameters within the same experimental system. That combination is important because it moves beyond simple metabolic assays and toward a more complete picture of how a compound may behave in the body after administration.
For drug developers, this type of integrated data could be especially valuable in early-stage decision-making. A more accurate understanding of clearance mechanisms and distribution behavior may help companies identify problematic compounds earlier, refine candidate selection and improve dose projection before entering human trials.
Combining multi-MPS data with PBPK modeling to generate clinical predictions
A central advance described in the study is not only the creation of the multi-tissue chip itself, but also the way the resulting biological data were translated into human clinical exposure predictions. Javelin said the platform’s on-chip parameters were validated through integration with PBPK models, a computational framework used to simulate how drugs move through the body based on physiological and biochemical parameters.
PBPK modeling has become an increasingly important tool in pharmaceutical research because it allows developers to combine experimental data with mathematical representations of human physiology. When done well, it can help estimate plasma exposure, tissue distribution, clearance and other pharmacokinetic outcomes under different dosing scenarios. However, the quality of PBPK predictions depends heavily on the quality and relevance of the input data.
That is where Javelin sees its platform as making a meaningful contribution. By generating human-relevant pharmacokinetic parameters directly from an interconnected multi-organ chip system, the company believes it can provide more predictive inputs for PBPK models than traditional preclinical approaches. In the published work, the integrated platform reportedly showed high correlation with human clinical data across all Extended Clearance Classification System (ECCS) classes, suggesting that the approach may be broadly applicable across different types of small-molecule drugs.
The ability to perform well across ECCS classes is notable because those categories reflect different mechanisms of drug clearance and disposition. Demonstrating predictive value across that range suggests the platform may be useful not just for a narrow subset of compounds, but potentially across a broader spectrum of small-molecule programs.
A step forward for New Approach Methodologies in drug development
Javelin Biotech is framing the publication as a major achievement in the evolving field of NAMs. These methodologies, which include organ-on-chip systems, advanced cell-based assays, in silico modeling and other alternatives to traditional animal studies, have gained increasing attention from regulators, pharmaceutical companies and technology developers seeking better ways to evaluate drug candidates.
Murat Cirit, Ph.D., Javelin Biotech’s chief executive officer, said the study provides strong evidence that multi-MPS platforms can deliver clinically relevant predictions, a milestone he described as particularly important given the scale of small-molecule development in today’s pipeline. According to Cirit, small molecules still account for about 50% of therapeutics currently in development, meaning there remains a substantial need for better translational tools in this area.
He also linked the publication to the broader policy and regulatory momentum around reducing animal use in drug development. Referencing the first anniversary of the FDA Modernization Act 3.0, Cirit said the study provides critical scientific support for the idea that Javelin’s platform can help accelerate development while generating clinical predictions without relying on animal data. The FDA modernization efforts have been closely watched by the industry because they reflect a growing openness to alternative preclinical methods that may complement or, in some cases, reduce the need for traditional animal studies.
For Javelin, the publication appears to serve both as scientific validation and as a strategic positioning statement. The company is making the case that its platform is not simply an experimental organ-chip tool, but a translational engine capable of producing data that matter in real development decisions.
Pfizer collaboration highlights industry interest in more predictive preclinical tools
The study also carries weight because it involves collaboration with Pfizer, one of the largest pharmaceutical companies in the world. R. Scott Obach, Ph.D., Senior Research Fellow at Pfizer, said the work aligns with Pfizer’s commitment to the 3Rs—replacement, reduction and refinement of animal use—and its broader efforts to improve the predictive accuracy of preclinical research.
Obach described the collaboration as an important step toward bridging the gap between laboratory models and clinical reality. He emphasized that integrating on-chip data into PBPK models helps build a deeper understanding of human-specific pharmacokinetics, which remains a crucial challenge in drug development. His comments suggest that large pharmaceutical companies are increasingly interested not just in organ-chip platforms themselves, but in complete translational frameworks that connect experimental biology with computational prediction and clinical relevance.
That distinction matters. In recent years, organ-chip technologies have attracted significant attention, but one of the key questions has been whether they can move beyond being interesting laboratory models to become tools that materially improve R&D decision-making. By showing how data from a multi-organ chip can feed directly into PBPK modeling and align with human clinical data, the Javelin-Pfizer collaboration appears to offer a stronger case for real-world utility.
It also reinforces the idea that future preclinical development may rely less on single-model systems and more on combinations of experimental and computational approaches that work together. Rather than asking one assay or one animal model to answer every pharmacokinetic question, companies may increasingly build integrated workflows that combine human-relevant tissue models with predictive software tools.
Why this matters for small-molecule drug development
Although the life sciences industry has devoted enormous attention in recent years to biologics, cell therapies and gene editing, small molecules remain a foundational part of the global therapeutic pipeline. They are used across oncology, inflammation, neurology, infectious disease and many other therapeutic areas, and they often remain attractive because of their oral dosing potential, manufacturing scalability and broad commercial applicability.
Yet predicting the pharmacokinetics of small molecules in humans remains a difficult task. A compound’s behavior can be shaped by multiple interacting factors, including metabolism, transport, protein binding, renal elimination and tissue distribution. Small errors in understanding these processes can lead to poor dose selection, unexpected toxicity, or failure to achieve sufficient therapeutic exposure.
Javelin’s platform is designed to help tackle exactly that challenge by creating a more integrated and mechanistic picture of drug disposition before first-in-human studies begin. If validated more broadly, such systems could improve candidate prioritization, reduce late-stage surprises and help companies refine development strategies earlier in the process.
The ability to estimate clinical exposure more accurately before human trials could also support smarter trial design, potentially lowering risk and reducing the number of costly iterations needed once a drug enters the clinic. For biopharma companies under pressure to make development more efficient, tools that improve translational confidence are likely to become increasingly important.
A bridge between the lab and the clinic
Javelin Biotech’s new publication ultimately speaks to a larger shift underway in pharmaceutical R&D: the movement toward data-driven, human-relevant preclinical methodologies that can bridge the gap between in vitro testing and clinical outcomes. The company argues that its multi-MPS platform, when paired with PBPK modeling, can serve as exactly that kind of bridge—linking laboratory biology with clinically meaningful pharmacokinetic prediction.
That vision is especially relevant as regulators, drug developers and investors place greater emphasis on translational efficiency, scientific rigor and reduced animal use. If organ-chip and computational systems can reliably predict how drugs behave in humans, they could reshape how early drug development is conducted across the industry.
For now, Javelin’s study stands as an important proof point in that direction. By demonstrating that a liver-centric multi-tissue chip integrated with PBPK modeling can reproduce human pharmacokinetic behavior across multiple clearance classes, the company has added to the growing body of evidence that next-generation NAMs may become a serious part of mainstream drug development infrastructure.
While more validation and broader adoption will still be needed, the publication positions Javelin Biotech as a company trying to push organ-chip science beyond proof-of-concept and into practical clinical prediction. In an industry searching for better ways to forecast human outcomes earlier and more accurately, that could prove to be a meaningful step forward.
About Javelin Biotech
Born from MIT’s interdisciplinary ecosystem, Javelin is a leading biotechnology company providing cutting-edge organ-on-a-chip platforms that offer unparalleled fidelity and insight into human biology and disease states. Our technology generates high-quality, human-relevant data essential for robust AI/ML integration, accelerating the development of safer, more effective, and personalized therapeutics while reducing costs and the reliance on animal testing.
